Grant and Funding Programs Offered by Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC)

The Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC) is a registered Canadian charity focused exclusively on Waldenström’s macroglobulinemia, a rare blood cancer. Operating nationally, it provides information, peer support and educational resources to Canadians with WM and their families, while also investing in research that aims to improve diagnosis, treatment and, ultimately, find a cure.

Beyond its educational mandate, WMFC plays a direct role in the research funding landscape. The organization co-funds WM-focused research projects at Canadian institutions, such as cutting-edge studies at the Odette Cancer Centre, Sunnybrook Hospital in Toronto. Through its “WMFC Supported Research” portfolio and collaborations with international partners, WMFC helps advance clinical and translational research on WM.

WMFC’s funding activity includes supporting clinical trials and operating grants that target Waldenström’s macroglobulinemia. For example, the foundation has participated in co-funding research at Sunnybrook linked to the BRAWM trial and related biological studies. It has also partnered with the Leukemia and Lymphoma Society of Canada (LLSC) to sponsor a WM-focused Operating Grant, a two-year research grant administered through LLSC and available to investigators at Canadian institutions who work on WM and other blood cancers.

In addition to these structured grants, WMFC collaborates with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) and other patient and research organizations worldwide. Through these alliances, WMFC channels donor contributions into high-impact projects, supports emerging therapies and encourages Canadian participation in international trials.

Funding activities are complemented by a strong educational and support infrastructure. WMFC organizes Educational Forums in major Canadian cities and virtually, bringing together leading researchers, clinicians and patients to discuss current treatment options, complications, quality-of-life issues and research progress. Many of these sessions are recorded and shared online, often with professionally translated French subtitles to ensure accessibility across Canada.

The foundation also maintains a comprehensive library of booklets, fact sheets, treatment option guides, videos, articles and newsletters. Regular communications, such as the WMFC newsletters and the “WM in Canada” article series, provide updates on funded research, clinical trials available in Canada and changes in access to therapies.

WMFC serves Canadians diagnosed with WM, their caregivers and families, regardless of where they live in the country. Its support groups, Canadian Lifeline peer connections and online discussion platforms help reduce isolation and enable patients to share experiences and coping strategies. At the same time, WMFC’s role as a funder and co-funder of WM research ensures that Canadian clinicians and scientists have additional resources to explore new treatments and deepen understanding of this rare lymphoma.

Through this dual mandate of patient support and research funding, the Waldenstrom’s Macroglobulinemia Foundation of Canada occupies a key niche in the Canadian cancer funding ecosystem, linking donors, researchers, clinicians and patients to accelerate progress against WM.